Indaptus appoints Robert Martell, M.D., Ph.D. to Board of Directors

Indaptus Therapeutics, Inc.

Board size increased to nine; Martell appointed Class I director effective Feb 13, 2023.
Annual retainer of $50,000 for Board service; standard indemnification agreement.
Received initial option for 20,000 shares at $1.71/share (fair market value on grant date).
Annual equity award up to $75,000 value (Black-Scholes) vesting on first anniversary or upon change of control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Martell

Class I director

INDP · Indaptus Therapeutics, Inc.

Effective: 2023-02-13
Filed: February 14, 2023, 6:59 PM ET

On February 13, 2023 (the “Effective Date”), the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size to provide for a total of nine directors authorized to serve on the Board and appointed Robert Martell, M.D., Ph.D. as a Class I director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert Martell was appointed as Class I director at Indaptus Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On February 13, 2023 (the “Effective Date”), the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size to provide for a total of nine directors authorized to serve on the Board and appointed Robert Martell, M.D., Ph.D. as a Class I director of the Company.

View on SEC.gov

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-004613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.